1.png)
Medivir AB, a research-based pharmaceutical company, has announces that Ola Burmark, chief financial officer at Medivir will be leaving his position. He will continue to fulfill his duties until end of August. A recruitment process has begun to find his replacement.
“Medivir has transformed into an oncology-focused research and development company with a broad pipeline of attractive projects. Ola has been an instrumental part of the executive leadership team in creating the new company and I want to thank him for his contributions and wish him good luck in his future career,” says Christine Lind, chief executive officer of Medivir.
“I have had a rewarding and instructive time at Medivir and the privilege to be involved in the most intense years of the company’s changes. Medivir is on a new journey with a vision to improve life for cancer patients through the development of transformative drugs and thus this is a good time to transition”, says Ola Burmark.
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs.
Ola burmark, chief financial officer, medivir resigns
